A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Clinical trial NCT07205796 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07205796
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-01
- Primary completion
- 2027-12-30
- Enrollment
- 480
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.